Post by icemandios on Mar 15, 2022 12:56:57 GMT
University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
PR Newswire
Center Becomes First MRIdian Program in Southern Europe to Reach this Treatment Milestone
CLEVELAND , March 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that University Hospital Agostino Gemelli has surpassed the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. University Hospital Agostino Gemelli is the fifth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.
The University Hospital Agostino Gemelli Radiation Oncology Department is a highly specialized center offering inpatients and outpatients cutting-edge clinical and technological treatment and began treating patients with MRIdian in February 2017 , treating more than 250 patients in 2021. Currently more than 50 percent of MRIdian treatments at University Hospital Agostino Gemelli are stereotactic body radiation therapy treatments (SBRT), which precisely delivers higher doses of radiation in 5 or fewer fractions. Nearly 25 percent of their MRIdian SMART treatments are for liver and pancreatic cancers, which take advantage of the system's MRI-guidance and real-time tissue tracking and automatic beam gating technology.
"As the second European medical facility to adopt MRI-guided radiotherapy, we have experienced first how how this technology has transformed our practice by allowing us to treat a longstanding clinical challenge, by enabling us to see the targeted tumor and the surrounding healthy tissue during treatment and ensure that the radiation beam stays within desired margins as tumors or organs move or deform," said Prof. Vincenzo Valentini , Head of Department of Dignostic, Imaging, Oncology Radiotherapy and Hematolgy. "Real-time MR imaging is especially useful for those tumors that often change position in unpredictable ways, allowing us to turn the beam off until the tumor returns to its known location."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Nearly 18,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: viewray.com/find-mridian-mri-guided-radiation-therapy/
Disclaimer:
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
PR Newswire
Center Becomes First MRIdian Program in Southern Europe to Reach this Treatment Milestone
CLEVELAND , March 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that University Hospital Agostino Gemelli has surpassed the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. University Hospital Agostino Gemelli is the fifth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.
The University Hospital Agostino Gemelli Radiation Oncology Department is a highly specialized center offering inpatients and outpatients cutting-edge clinical and technological treatment and began treating patients with MRIdian in February 2017 , treating more than 250 patients in 2021. Currently more than 50 percent of MRIdian treatments at University Hospital Agostino Gemelli are stereotactic body radiation therapy treatments (SBRT), which precisely delivers higher doses of radiation in 5 or fewer fractions. Nearly 25 percent of their MRIdian SMART treatments are for liver and pancreatic cancers, which take advantage of the system's MRI-guidance and real-time tissue tracking and automatic beam gating technology.
"As the second European medical facility to adopt MRI-guided radiotherapy, we have experienced first how how this technology has transformed our practice by allowing us to treat a longstanding clinical challenge, by enabling us to see the targeted tumor and the surrounding healthy tissue during treatment and ensure that the radiation beam stays within desired margins as tumors or organs move or deform," said Prof. Vincenzo Valentini , Head of Department of Dignostic, Imaging, Oncology Radiotherapy and Hematolgy. "Real-time MR imaging is especially useful for those tumors that often change position in unpredictable ways, allowing us to turn the beam off until the tumor returns to its known location."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Nearly 18,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: viewray.com/find-mridian-mri-guided-radiation-therapy/
Disclaimer:
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.